AIM ImmunoTech : Provides Progress on Advancement of Ampligen® Clinical Development Program for the Treatment of Pancreatic Cancer - Form 8-K
AIM ImmunoTech Inc. , an immuno-pharma company focused on the research and development of therapeutics to treat multiple types of cancers, immune disorders, and viral diseases, including COVID-19,... | April 12, 2022
Source: marketscreener.com